BioAdvance Announces ~$7M in Recent Investments and Leadership Transition
Barbara Schilberg retiring as Managing Director and CEO;
Shahram Hejazi, Ph.D., appointed as Managing Director and CEO
BioAdvance Announces ~$7M in Recent Investments and Leadership Transition
Barbara Schilberg retiring as Managing Director and CEO;
Shahram Hejazi, Ph.D., appointed as Managing Director and CEO
Renovacor Announces the Appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science
Dr. Shin to help advance REN-001 into the clinic by leveraging nearly two decades of expertise in clinical development, academic research and medical practice
Syneos Health and Ride Health Partner to Improve Clinical Trial Recruitment and Retention
Partnership Creates a More Patient-centric Travel Experience, Drives Adherence and Advances Diversity and Inclusion in Clinical Research
Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing
– IMM-BCP-01 already shown to neutralize all other Centers for Disease Control (CDC) variants of concern in pre-clinical testing
Renovacor Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange
Common stock and warrants of the combined company, renamed Renovacor, Inc., will commence trading on September 3, 2021 on the NYSE under ticker symbols “RCOR” and “RCOR.WS”, respectively.
Gross proceeds from the transaction totaled approximately $95.1 million.
Phrase Health Awarded Phase 2 NIH Grant To Scale Quality Improvement Platform
The $1.7 million Phase 2 STTR grant expands upon the quality improvement and informatics cloud-based software developed by the company
ImmunoGenesis Announces Positive Preclinical Glioblastoma and Pancreatic Cancer Data for STimulator of INterferon Genes (STING) Agonist Published in Two Scientific Journals
STING agonist can induce innate immune responses that allow the immune system to fight otherwise immunologically resistant cancers
Phase 1 canine glioblastoma veterinary trial data show the promise of STING agonist as potential future therapy for human glioblastoma
Data support the advancement of ImmunoGenesis’ STING-Immune Stimulating Antibody Conjugate (ISAC) in immunologically cold tumors
Centers for Medicare & Medicaid Services Issues New Code for Encala®
Code S9432 Will Provide Improved Access for Individuals with Malabsorption and Take Effect October 1, 2021
Renovacor Announces the Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer
Dr. Killeen joins Renovacor from BioMarin where he led the discovery and development of AAV-based gene therapies for inherited cardiac diseases
Venatorx Pharmaceuticals Provides Update on Cefepime-Taniborbactam
Topline Data from Phase 3 clinical trial of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs) expected first quarter 2022
BARDA extends cost-sharing contract to support the development of cefepime-taniborbactam in patients with hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia (HABP/VABP)
Phase 3 clinical trial of cefepime-taniborbactam in patients with HABP/VABP scheduled to begin in 2022